[Substitution treatment of hemophilia a and b].
The availability of factor VIII and factor IX concentrates has considerably improved substitution therapy in hemophilia A and B respectively. The desired activity levels and the corresponding factor VIII or factor IX dosage are indicated. Antifibrinolyics have a favorable action when given simultaneously, though hematuria is an absolute contraindication for antifibrinolytic treatment. The administration of factor IX concentrate in case of hemorrhage due to oral anticoagulation or to liver disease, or in newborns, should be used in emergency situations only, since this material may provoke either thrombosis or disseminated intravascular coagulation. Transmission of hepatitis is also possible.
D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D005164:Factor IX / Q000627:therapeutic use; D005169:Factor VIII / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy / Q000628:therapy*; D002836:Hemophilia B / Q000188:drug therapy / Q000628:therapy*; D006470:Hemorrhage / Q000517:prevention & control; D006487:Hemostasis; D006801:Humans; D008297:Male; D011300:Preoperative Care
D000933:Antifibrinolytic Agents; D005169:Factor VIII; D005164:Factor IX
Le traitement substifutif de l'héhophilie A et B